The activities of teicoplanmn and vancomycin against 362 coagulase-negative staphylococci were determined by an agar dilution method. At 
Teicoplanin is a valuable drug for the treatment of infections caused by methicillin-resistant staphylococci, which represent 35 to 50% of all staphylococci isolated in our hospital. Teicoplanin is more active than vancomycin against streptococci and enterococci and equally active against Staphylococcus aureus but less active against coagulase-negative staphylococci. Few teicoplanin-resistant coagulase-negative staphylococci have been reported (1, 2, (4) (5) (6) (7) 9 This study demonstrated that susceptibility of coagulasenegative staphylococci to teicoplanin cannot be inferred from results of tests of vancomycin susceptibility and should be routinely determined, at least for patients treated with teicoplanin.
Vancomycin and teicoplanin are widely used in our hospital because of the prevalence of methicillin-resistant S. aureus. However, most of the teicoplanin-resistant strains were isolated from patients not previously treated with vancomycin or teicoplanin.
Further studies are necessary to determine (i) the role of vancomycin and teicoplanin in the increase in teicoplanin- 
